Live Analyst Rating Changes 36626 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andres Y. Maldonado
HC

Andres Y. Maldonado

H.C. Wainwright
Wall Street Analyst
★★☆☆☆
#2246
on 13Foresight · ranked by our own returns
38%
Success Rate
-1.0%
Average Return
32 of 84 calls profitable · -166.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 38% of Andres Y. Maldonado's ratings turned a profit when each position was held for 1 year — averaging -1.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

191 Buy 6 Hold 0 Sell
Andres's Stock Coverage 23 ratings · 2026-10-04
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SNDX
Syndax Pharmaceuticals
 Oct 01, 2026 BUY Strong Buy
+98.5% avg upside
27 analysts
$38.00
115.98% Upside
 -3.4% ·
CADL
Candel Therapeutics
 Sep 30, 2026 BUY Strong Buy
+86.6% avg upside
11 analysts
$23.00
125.90% Upside
 · ·
IMRX
Immuneering
 Sep 25, 2026 BUY Strong Buy
+343.8% avg upside
12 analysts
$14.00
243.93% Upside
 -4.7% ·
MNPR
Monopar Therapeutics Inc
 Sep 21, 2026 BUY Strong Buy
+36.2% avg upside
18 analysts
$125.00
60.40% Upside
 -16.4% ·
NBP
NovaBridge Biosciences
 Sep 21, 2026 BUY Strong Buy
+1461.0% avg upside
14 analysts
$9.00
564.22% Upside
 -15.8% ·
STRO
Sutro Biopharma
 Sep 21, 2026 BUY Strong Buy
+171.9% avg upside
22 analysts
$50.00
225.77% Upside
 -1.5% ·
TARA
Protara Therapeutics
 Sep 21, 2026 BUY Strong Buy
+1804.3% avg upside
21 analysts
$27.00
900.02% Upside
 -23.1% ·
VSTM
Verastem
 Sep 21, 2026 BUY Strong Buy
+99.9% avg upside
24 analysts
$18.00
133.79% Upside
 -3.6% ·
CRBP
Corbus Pharmaceuticals
 Sep 15, 2026 BUY Strong Buy
+467.6% avg upside
20 analysts
$35.00
470.88% Upside
 -11.4% ·
SRRK
Scholar Rock Holding
 Sep 15, 2026 BUY Strong Buy
+39.9% avg upside
23 analysts
$70.00
49.63% Upside
 -6.4% ·
IMNM
Immunome
 Sep 11, 2026 BUY Strong Buy
+57.8% avg upside
18 analysts
$40.00
91.45% Upside
 -13.2% ·
ENGN
enGene Holdings
 Sep 09, 2026 BUY Buy
+414.9% avg upside
13 analysts
$4.00
106.14% Upside
 +4.9% ·
TCRX
TScan Therapeutics
 Sep 09, 2026 HOLD Buy
+2292.1% avg upside
12 analysts
$1.00
212.10% Upside
 -3.6% ·
AURA
Aura Biosciences Inc
 Aug 12, 2026 BUY Strong Buy
+233.1% avg upside
9 analysts
$18.00
195.48% Upside
 -21.4% ·
ERAS
Erasca
 Aug 12, 2026 BUY Strong Buy
+42.5% avg upside
14 analysts
$22.00
49.26% Upside
 -20.7% ·
RLMD
Relmada Therapeutics
 Aug 10, 2026 BUY Buy
+271.2% avg upside
15 analysts
$12.00
233.36% Upside
 -20.7% ·
ZNTL
Zentalis Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+432.3% avg upside
20 analysts
$10.00
296.75% Upside
 -35.7% ·
CGON
CG Oncology, Inc.
 Aug 07, 2026 BUY Strong Buy
+27.6% avg upside
17 analysts
$100.00
48.31% Upside
 -10.3% ·
FHTX
Foghorn Therapeutics
 Aug 07, 2026 BUY Buy
+399.9% avg upside
17 analysts
$13.00
543.54% Upside
 -42.0% ·
KROS
Keros Therapeutics
 Aug 04, 2026 BUY Strong Buy
+110.7% avg upside
21 analysts
$20.00
76.10% Upside
 +9.8% ·
IBRX
ImmunityBio
 Aug 04, 2026 BUY Strong Buy
+9.3% avg upside
12 analysts
$15.00
45.81% Upside
 +46.0% ·
HOWL
Werewolf Therapeutics
 Dec 19, 2025 BUY Strong Buy
+643.5% avg upside
8 analysts
$4.00
331.03% Upside
 +28.4% ·
IMA
ImageneBio
 Nov 11, 2024 BUY Strong Buy
+288.1% avg upside
13 analysts
$4.00
13.12% Downside
 -59.0% ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andres Y. Maldonado — Frequently Asked Questions
How accurate are Andres Y. Maldonado's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Andres's ratings were profitable over a one-year hold, with an average return of -1.0% per rating, or -2.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andres ranked on 13Foresight?
Andres Y. Maldonado is currently ranked #2246 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andres cover?
Andres most recently has ratings on SNDX, CADL, IMRX, MNPR, NBP, STRO, TARA, VSTM, CRBP, SRRK, IMNM, ENGN and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.